시장보고서

상품코드

1555475

항진균제 시장 : 약제 클래스별, 적응증별, 투여 경로별, 감염 유형별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Antifungal Drugs Market, By Drug Class, By Indication, By Route of Administration, By Infection Type, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 08월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 388 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

항진균제 시장 규모는 2023년에 156억 7,823만 달러에 달하며, 2024-2032년 CAGR 3.79%로 확대

항진균제 시장 - 시장 역학

진균 감염증의 만연이 시장 성장을 촉진할 것으로 예측

칸디다증, 아스페르길루스증, 크립토코커스증과 같은 진균 감염은 특히 HIV/AIDS 환자, 암 환자, 장기 이식 환자 등 면역력이 저하된 환자들 사이에서 점점 더 많이 발생하고 있습니다. 이러한 감염 빈도 증가는 인식의 향상과 진단 툴의 가용성 향상과 함께 효과적인 항진균 치료제에 대한 수요를 견인하고 있습니다. 미국 질병예방통제센터(CDC)에 따르면 연간 75,000명 이상이 진균증으로 입원하고 900만 명에 가까운 외래환자가 진균증으로 인해 치료를 받고 있습니다. 또한 새로운 약물 계열과 혁신적인 제형 개발 등 항진균 치료제의 연구개발이 활발히 진행되고 있는 것도 큰 시장 기회를 가져오고 있습니다. 하지만 높은 치료비용은 시장 확대에 걸림돌이 될 수 있습니다.

항진균제 시장 - 주요 인사이트

당사의 리서치 분석가들의 분석에 따르면 세계 시장은 예측 기간(2024-2032년) 동안 연평균 약 3.79%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

약물 유형별로는 아졸계 약물이 22023년 가장 높은 시장 점유율을 차지했습니다.

적응증별로는 2023년 칸디다증이 주요 유형으로 나타났습니다.

투여 경로별로는 2023년 경구제가 주요 유형으로 나타났습니다.

감염 유형별로는 2023년에는 전신 항진균 감염이 주요 유형으로 나타났습니다.

유통 채널별로는 2023년 병원 약국이 주요 유형이었습니다.

지역별로는 북미가 2023년 매출 1위를 차지했습니다.

항진균제 시장 - 세분화 분석 :

세계 항진균제 시장은 약제 유형별, 적응증별, 투여 경로별, 감염 유형별, 유통 채널별, 지역별로 구분됩니다.

약물 유형에 따라 시장은 아졸계, 에키노칸딘계, 폴리엔계, 알릴아민계, 기타로 나뉩니다. 아졸계 항진균제는 시장에서 압도적인 위치를 차지하고 있습니다. 이 계열의 항진균제는 많은 진균 감염증 치료에 널리 사용되고 있습니다. 작용기전은 곰팡이 세포막의 중요한 요소인 에르고스테롤 합성을 억제하여 결국 곰팡이를 죽이는 것입니다.

시장은 적응증에 따라 피부사상균증, 아스페르길루스증, 칸디다증, 기타 세 가지 범주로 나뉩니다. 칸디다증은 시장에서 우위를 점하고 있습니다. 칸디다 종에 의해 발생하는 이 질환은 표재성 및 전신 침습성 형태로 나타날 수 있는 전염성 진균 감염입니다. 칸디다증에 대한 항진균제 선택은 감염의 중증도, 감염 부위, 면역 상태, 과거 치료 여부 등 환자별 요인에 따라 달라집니다.

시장은 투여 경로에 따라 경구제, 국소제, 주사제의 세 가지 부문으로 나뉩니다. 시장을 주도하는 것은 경구제입니다. 경구용 항진균제는 구강내 진균 감염(흔히 구강 칸디다증 또는 구내염이라고도 함)을 치료하는 데 사용됩니다.

시장은 감염 유형에 따라 전신 항진균 감염과 표재성 항진균 감염의 두 가지 부문으로 나뉩니다. 전신 항진균 감염은 시장에서 우위를 점하고 있습니다. 전신 항진균 감염의 치료는 심각한 진균 감염증에 대처하는 데 매우 중요하며, 특정 곰팡이 병원체와 환자의 상태에 따라 적절한 항진균제를 선택해야 합니다.

시장은 유통 채널에 따라 병원 약국, 소매 약국, 기타 두 가지 부문으로 나뉩니다. 병원 약국은 시장에서 지배적 인 위치를 차지하고 있습니다. 병원 약국은 의약품의 선택, 준비 및 투여를 담당하여 효과적이고 안전한 치료를 실현합니다.

항진균제 시장 - 지역적 인사이트

항진균제 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카를 포함한 광범위한 지역에 걸쳐 있습니다. 이 지역은 사업 활동에 기여하는 국가를 기준으로 더 세분화됩니다. 북미는 첨단화된 의료 인프라와 양질의 의료 시설로 인해 시장을 선도하고 있습니다. 특히 미국은 최첨단 병원, 연구 기관 및 진단센터를 갖춘 고도로 발달된 의료 시스템을 갖추고 있습니다. 감염성 질환 전문센터를 포함한 첨단 의료 시설의 존재는 진균 감염증증의 신속하고 정확한 진단을 용이하게 합니다. 최근 데이터와 보고서에 따르면 2021년 미국의 총 의료비는 4조 3,000억 달러에 달하고, 국내총생산(GDP)의 18.5%를 차지할 것으로 예측됩니다. 유럽은 정부 및 민간 부문의 투자 증가로 인해 시장 성장률 2위 지역으로 부상했습니다.

항진균제 시장 - 경쟁상황:

항진균제 시장의 경쟁 환경은 약물의 효능, 안전성 프로파일, 제형 발전, 가격 전략 등 다양한 요인에 의해 영향을 받고 있습니다. 각 업체들은 새로운 항진균제 화합물 발견, 기존 제제 개선, 약물 내성 문제 해결을 위한 연구개발에 많은 자원을 투입하고 있습니다. 주요 경쟁 요소로는 약물전달 시스템의 혁신, 병용 요법, 새로운 계열의 항진균제 도입 등이 있습니다. 기업은 특히 진균 감염증이 큰 도전이 되고 있는 신흥 시장에서 지역적 입지를 확대하기 위해 노력하고 있습니다. 시장 입지를 구축하기 위한 일반적인 전략으로는 전략적 파트너십 형성, 인수 추진, 현지 제조 진출 등이 있습니다. 내성균에 대한 치료법을 개발하거나 새로운 치료 옵션을 제공하는 데 집중하는 기업은 시장에서 더 강력한 입지를 확보할 가능성이 높습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제13장 주요 벤더 분석 - 항진균제 업계

경쟁 대시보드
기업 개요
- Novartis AG
- Pfizer, Inc.
- Bayer AG
- Sanofi
- Merck &Co., Inc.
- GlaxoSmithKline plc
- Abbott
- Glenmark
- Enzon Pharmaceuticals, Inc.
- Astellas Pharma, Inc.
- 기타

제14장 애널리스트의 전방위 전망

KSA 24.10.16

REPORT HIGHLIGHT

Antifungal Drugs Market size was valued at USD 15,678.23 Million in 2023, expanding at a CAGR of 3.79% from 2024 to 2032.

Antifungal medications are utilized to address fungal infections. Fungi present in the soil, air, and on the skin can result in conditions such as yeast infections, ringworm, and infections affecting the nails and skin. Inhalation of fungal spores may result in respiratory ailments. Individuals with compromised immune systems are at a higher risk for fungal infections that necessitate antifungal treatment. A range of antifungal drugs is available to combat these infections, with some being accessible over the counter while others require a prescription, contingent upon the specific medication.

Antifungal Drugs Market- Market Dynamics

The growing prevalence of fungal infections is anticipated to drive the growth of the market

Fungal infections, including candidiasis, aspergillosis, and cryptococcosis, are increasingly prevalent, especially among individuals with compromised immune systems, such as those suffering from HIV/AIDS, cancer, or those who have undergone organ transplants. The rising frequency of these infections, along with enhanced awareness and the availability of diagnostic tools, is driving the demand for effective antifungal therapies. According to the Centers for Disease Control and Prevention, over 75,000 hospitalizations and nearly 9 million outpatient visits for fungal diseases occur annually. Additionally, ongoing research and development in antifungal treatments, which includes the identification of new drug classes and innovative formulations, present substantial market opportunities. Nevertheless, the high cost of treatment may pose a challenge to market expansion.

Antifungal Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.79% over the forecast period (2024-2032)

Based on Drug Class segmentation, Azoles was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Candidiasis was the leading type in 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on Infection Type segmentation, Systemic antifungal infections were the leading type in 2023

Based on Distribution Channel segmentation, Hospital pharmacies were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Antifungal Drugs Market- Segmentation Analysis:

The Global Antifungal Drugs Market is segmented based on Drug Class, Indication, Route of Administration, Infection Type, Distribution Channel, and Region.

The market is segmented into three categories according to Drug Class: Azoles, Echinocandins, Polyenes, Allylamines, and Others. Azoles hold a dominant position in the market. This class of antifungal medications is widely utilized for the treatment of numerous fungal infections. Their mechanism of action involves the inhibition of ergosterol synthesis, a crucial element of fungal cell membranes, resulting in the eventual demise of the fungus.

The market is segmented into three categories according to Indication: Dermatophytosis, Aspergillosis, Candidiasis, and Others. Candidiasis holds a predominant position in the market. This condition, resulting from Candida species, represents a prevalent fungal infection that can manifest in both superficial and systemic, invasive forms. The selection of antifungal medications for candidiasis is influenced by the severity and location of the infection, as well as patient-specific factors, including immune status and previous treatments.

The market is classified into three segments according to Route of administration: Oral, Topical, and Injectable. The Oral segment leads the market. Oral antifungal medications are utilized to address fungal infections within the oral cavity, frequently referred to as oral candidiasis or thrush.

The market is categorized into two segments according to Infection Type: Systemic antifungal infections and superficial antifungal infections. Systemic antifungal infections hold a predominant position in the market. The treatment of systemic antifungal infections is crucial for addressing severe fungal infections and requires the selection of a suitable antifungal agent based on the specific fungal pathogen and the patient's condition.

The market is categorized into two segments based on Distribution Channels: Hospital pharmacies, Retail pharmacies, and others. Hospital pharmacies hold a dominant position in the market. They are tasked with the selection, preparation, and administration of medications, thereby ensuring both effective and safe treatment.

Antifungal Drugs Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads the market, attributed to its advanced healthcare infrastructure and high-quality medical facilities. The United States, in particular, features a highly developed healthcare system, equipped with cutting-edge hospitals, research institutions, and diagnostic centers. The presence of advanced medical facilities, including specialized centers for infectious diseases, facilitates prompt and precise diagnosis of fungal infections. Recent data and reports indicate that total healthcare expenditure in the United States for 2021 is projected to reach USD 4.3 trillion, representing 18.5% of the nation's GDP. Europe ranks as the second-largest region for market growth, driven by increased investments from both government and private sectors.

Antifungal Drugs Market- Competitive Landscape:

The competitive landscape of the antifungal drugs market is influenced by various factors, including the effectiveness of medications, safety profiles, advancements in formulations, and pricing strategies. Organizations allocate substantial resources to research and development aimed at discovering novel antifungal compounds, enhancing current formulations, and tackling issues related to drug resistance. Key competitive elements include innovations in drug delivery systems, combination therapies, and the introduction of new classes of antifungal agents. Companies strive to broaden their geographical presence, particularly in emerging markets where fungal infections pose a significant challenge. Common strategies for establishing a market presence include forming strategic partnerships, pursuing acquisitions, and engaging in local manufacturing. Firms that concentrate on developing treatments for resistant strains or providing new therapeutic options are likely to achieve a stronger position in the market.

Recent Developments:

In August 2023, Sandoz, a prominent global entity in the field of generic and biosimilar pharmaceuticals, announced the successful acquisition of the global brand rights for the renowned systemic antifungal medication Mycamine (micafungin sodium, known as Funguard in Japan) from Astellas.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIFUNGAL DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Novartis AG
Pfizer, Inc.
Bayer AG
Sanofi
Merck & Co., Inc.
GlaxoSmithKline plc
Abbott
Glenmark
Enzon Pharmaceuticals, Inc.
Astellas Pharma, Inc.
Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

Azoles
Echinocandins
Polyenes
Allylamines
Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Dermatophytosis
Aspergillosis
Candidiasis
Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Topical
Injectable

GLOBAL ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE- MARKET ANALYSIS, 2019 - 2032

Systemic antifungal infections
Superficial antifungal infections

GLOBAL ANTIFUNGAL DRUGS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital pharmacies
Retail pharmacies
Others

GLOBAL ANTIFUNGAL DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Antifungal Drugs Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Antifungal Drugs Market Snippet by Drug Class
- 2.1.2. Antifungal Drugs Market Snippet by Indication
- 2.1.3. Antifungal Drugs Market Snippet by Route of Administration
- 2.1.4. Antifungal Drugs Market Snippet by Infection Type
- 2.1.5. Antifungal Drugs Market Snippet by Distribution Channel
- 2.1.6. Antifungal Drugs Market Snippet by Country
- 2.1.7. Antifungal Drugs Market Snippet by Region
2.2. Competitive Insights

3. Antifungal Drugs Key Market Trends

3.1. Antifungal Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Antifungal Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Antifungal Drugs Market Opportunities
3.4. Antifungal Drugs Market Future Trends

4. Antifungal Drugs Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Antifungal Drugs Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Antifungal Drugs Market Landscape

6.1. Antifungal Drugs Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Antifungal Drugs Market - By Drug Class

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 7.1.2. Azoles
- 7.1.3. Echinocandins
- 7.1.4. Polyenes
- 7.1.5. Allylamines
- 7.1.6. Others

8. Antifungal Drugs Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
- 8.1.2. Dermatophytosis
- 8.1.3. Aspergillosis
- 8.1.4. Candidiasis
- 8.1.5. Others

9. Antifungal Drugs Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Topical
- 9.1.4. Injectable

10. Antifungal Drugs Market - By Infection Type

10.1. Overview
- 10.1.1. Segment Share Analysis, By Infection, 2023 & 2032 (%)
- 10.1.2. Systemic antifungal infections
- 10.1.3. Superficial antifungal infections

11. Antifungal Drugs Market - By Distribution Channel

11.1. Overview
- 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 11.1.2. Hospital pharmacies
- 11.1.3. Retail pharmacies
- 11.1.4. Others

12. Antifungal Drugs Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Antifungal Drugs Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Antifungal Drugs Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.10. Italy
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.10.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.10.6. Italy Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.11. United Kingdom
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.3.11.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.11.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.11.6. United Kingdom Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.12. France
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.3.12.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.12.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.12.6. France Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.13. Russia
  - 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.3.13.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.13.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.13.5. Russia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.14. Netherlands
  - 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.3.14.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.14.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.14.5. Netherlands Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.16. Poland
  - 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.3.16.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Poland Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.17. Rest of Europe
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Rest of the Europe Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Antifungal Drugs Key Manufacturers in Asia Pacific
- 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.4.7. Asia Pacific Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
- 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.9. India
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.4.9.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.9.6. India Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.10. China
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.4.10.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.10.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.10.6. China Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.14. Thailand
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Thailand Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.15. Indonesia
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Indonesia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.5. Latin America
- 12.5.1. Overview
- 12.5.2. Antifungal Drugs Key Manufacturers in Latin America
- 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.5.7. Latin America Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
- 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Antifungal Drugs Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By Infection Type, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Antifungal Drugs Industry

13.1. Competitive Dashboard
13.2. Company Profiles
- 13.2.1. Novartis AG
- 13.2.2. Pfizer, Inc.
- 13.2.3. Bayer AG
- 13.2.4. Sanofi
- 13.2.5. Merck & Co., Inc.
- 13.2.6. GlaxoSmithKline plc
- 13.2.7. Abbott
- 13.2.8. Glenmark
- 13.2.9. Enzon Pharmaceuticals, Inc.
- 13.2.10. Astellas Pharma, Inc.
- 13.2.11. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us